Mercer Global Advisors’s Avalo Therapeutics AVTX Stock Holding History

Mercer Global Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.6K	Buy	+1,600	New	+$25.3K	﹤0.01%	4614

Other funds holding AVTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Mercer Global Advisors's AVTX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 1,600 shares worth $29.6K. The stake represents ﹤0.01% of the portfolio and ranks #4614 among its holdings.

99 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Mercer Global Advisors held 1,600 shares of Avalo Therapeutics worth $29.6K as of Q2 2026.
Avalo Therapeutics was a new Mercer Global Advisors position in Q2 2026.
Avalo Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4614 holding.
99 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.